Achillion Reports 2014 Fourth Quarter and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Data Could Lead to Achillion Pharmaceuticals (ACHN) Takeover By Year End - Analyst
March 6, 2015 1:32 PM ESTWilliam Blair analyst Y. Katherine Xu offered some interesting commentary on Achillion Pharmaceuticals (NASDAQ: ACHN) after the company's "uneventful" fourth quarter report. While keeping her Market Perform rating and lowering her price target to $14.00 (from $15.00), Xu highlighted that Achillion intends to initiate three different combination studies in the treatment of hepatitis C virus (HCV) during 2015 to... More
Achillion Pharma (ACHN) Misses Q4 EPS by 3c
March 5, 2015 6:08 AM ESTAchillion Pharma (NASDAQ: ACHN) reported Q4 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18).
2015 Financial Guidance
At December 31, 2014, Achillion had cash, cash equivalents, marketable securities and interest and subscription receivables of approximately $159.2 million. Achillion completed a public offering of common stock on February 18, 2015, and... More
